1 / 15

Clinical Presentation of Type 2 Diabetes

Clinical Presentation of Type 2 Diabetes. Risk Factors for Prediabetes and Type 2 Diabetes. Family history of diabetes mellitus Cardiovascular disease Being overweight or obese Sedentary lifestyle Nonwhite ancestry

azuka
Télécharger la présentation

Clinical Presentation of Type 2 Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Presentation of Type 2 Diabetes

  2. Risk Factors for Prediabetes and Type 2 Diabetes • Family history of diabetes mellitus • Cardiovascular disease • Being overweight or obese • Sedentary lifestyle • Nonwhite ancestry • Previously identified impaired glucose tolerance, impaired fasting glucose, and/or metabolic syndrome • Hypertension • Increased levels of triglycerides, low concentrations of high-density lipoprotein cholesterol, or both • History of gestational diabetes mellitus • Delivery of a baby weighing more than 4 kg (9 lb) • Polycystic ovary syndrome • Antipsychotic therapy for schizophrenia and/or severe bipolar disease HandelsmanY, et al. EndocrPract. 2011;17(suppl 2):1-53.

  3. Development of Type 2 Diabetes Depends on Interplay Between Insulin Resistance and β-Cell Dysfunction Genes & environment Genes & environment • Insulin resistance • No diabetes • Normalβ-Cell Function • Compensatory hyperinsulinemia • Type 2 diabetes • Insulin resistance • Abnormalβ-Cell Function • Relative insulin deficiency Gerich JE. Mayo Clin Proc. 2003;78:447-456.

  4. Etiology of β-cell Dysfunction Genetic predisposition • Lean phenotype • Obese phenotype • Elevated FFA • IGT, IFG • Initial glucolipoadaptation (increased FFA usage) • Hyperglycemia • Oxidative stress and glucotoxicity • Cellular lipid synthesis and glucolipotoxicity • Glucolipotoxicity and glucotoxicity • Progressive -cell failure and type 2 diabetes Poitout V, Robertson RP. Endocrine Rev. 2008;29:351-366.

  5. Nonprogressors NGT NGT NGT NGT IGT Progressors DIA Progression to Type 2 Diabetes: “Falling Off the Curve” 500 400 300 Acute insulin response (U/mL) 20 0 100 0 0 1 2 3 4 5 Glucose disposal (insulin sensitivity)(mg/kg EMBS/min) NGT=normal glucose tolerance; IGT=impaired glucose tolerance; EMBS=estimated metabolic body size. Weyer C et al. J Clin Invest. 1999;104:787-794.

  6. Pathophysiology of T2DM DeFronzo RA. Diabetes. 2009;58:773-795

  7. -Cell function Insulin resistance Insulin secretion Postprandial glucose Fasting glucose Macrovascular complications Natural History of Type 2 Diabetes Years from diagnosis 10 5 15 –10 –5 0 Onset Diagnosis Incretin effect Microvascular complications Prediabetes Type 2 diabetes Figure courtesy of CADRE. Adapted from Holman RR. Diabetes Res ClinPract. 1998;40(suppl):S21-S25;Ramlo-Halsted BA, Edelman SV. Prim Care. 1999;26:771-789; Nathan DM. N Engl J Med. 2002;347:1342-1349; UKPDS Group. Diabetes. 1995;44:1249-1258

  8. UKPDS: -cell Loss Over Time 100 – 75 – 50 – -Cell Function (%) Impaired Glucose Tolerance Postprandial Hyperglycemia 25 – Type 2 Diabetes 0 – l -12 l -10 l -6 l 0 l 2 l 6 l 10 l 14 l -2 Years from Diagnosis Dashed line = extrapolation based on Homeostasis Model Assessment (HOMA) data. Data points from obese UKPDS population, determined by HOMA model. Holman RR. Diabetes Res ClinPract. 1998;40(suppl):S21-S25.

  9. Normal Glucose Homeostasis and Pre- and Postmeal Insulin and Glucagon Dynamics Normal (n=11) 120 Meal 90 Insulin (µU/mL) 60 30 0 140 130 120 Glucagon (pg/mL) 110 100 90 360 330 300 Glucose (mg %) 270 240 110 80 -60 0 60 120 180 240 Time (min) Müller WA, et al. N Engl J Med. 1970;283:109-115.

  10. Hyperglycemia in Type 2 Diabetes Results from Abnormal Insulin and Glucagon Dynamics Normal (n=11) 120 Meal T2DM (n=12) 90 Insulin (µU/mL) 60 30 0 140 130 120 Glucagon (pg/mL) 110 100 90 360 330 300 Glucose (mg %) 270 240 110 80 -60 0 60 120 180 240 Time (min) Müller WA, et al. N Engl J Med. 1970;283:109-115.

  11. Acute Insulin Response Is Reduced in Type 2 Diabetes 1st 2nd phase 20 g glucose infusion 120 Normal (n=85) 100 Type 2 diabetes (n=160) 80 60 Plasma IRI (µU/ml) 40 20 0 -30 0 30 60 90 120 Time (minutes) IRI=immunoreactive insulin. Pfeifer MA, et al. Am J Med. 1981;70:579-588.

  12. 7 6 5 4 3 2 1 0 Defective Insulin Action in T2DM 12 8 Total Body Glucose Uptake (mg/kg • min) Leg Glucose Uptake (mg/kg leg wt per min) 4 P<0.01 0 Normal T2DM 0 20 60 100 140 180 Time (minutes) DeFronzo RA, et al. J Clin Invest. 1979;63:939-946; DeFronzo RA, et al. J Clin Invest. 1985;76:149-155.

  13. Elevated Fasting Glucose in Type 2 Diabetes Results From Increased HGP 4.0 3.5 r=0.85P<0.001 3.0 Basal HGP(mg/kg • min) 2.5 Control 2.0 T2DM 100 200 300 FPG (mg/dL) DeFronzo RA, et al. Metabolism. 1989;38:387-395.

  14. Type 2 Diabetes: A Progressive Disease 79,000,000 25,800,000 Primary prevention Secondary prevention Tertiary prevention Garber AJ, et al. Endocr Pract. 2008;14:933-46. CDC. National diabetes fact sheet, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.

  15. Summary: Hyperglycemia in Type 2 Diabetes • Hyperglycemia results from the combination of • Pancreatic -cell dysfunction, resulting in impaired insulin secretion • Increased hepatic glucose production due to excessive glucagon • Decreased peripheral glucose uptake due to insulin resistance Handelsman Y, et al.EndocrPract. 2011;17(suppl 2):1-53.

More Related